Nick Kaludov is a distinguished scientist and entrepreneur, currently serving as the Co-Founder and President of AliquantumRx Inc. (AQR), a pioneering start-up based in Maryland. With a robust background that intertwines biology, physics, and chemistry, Nick has dedicated his career to advancing drug discovery and...
Nick Kaludov is a distinguished scientist and entrepreneur, currently serving as the Co-Founder and President of AliquantumRx Inc. (AQR), a pioneering start-up based in Maryland. With a robust background that intertwines biology, physics, and chemistry, Nick has dedicated his career to advancing drug discovery and development, particularly in the realm of innovative therapeutics. At AQR, he is spearheading the development of Cethromycin, a macrolide antibiotic, with a vision to repurpose this compound for new therapeutic applications. The initial focus on liver-stage malaria, specifically targeting the dormant vivax form, underscores his commitment to addressing significant global health challenges.
Nick's expertise in big data analytics plays a crucial role in AQR's strategic approach, enabling the integration of complex datasets to inform drug development processes. His extensive experience in chromatography, proteomics, and biotechnology equips him with the necessary skills to lead multifaceted projects that require meticulous planning and execution. Under his leadership, AQR is also exploring the potential of Cethromycin to combat tick-borne diseases such as Babesiosis, as well as bioterror threats like inhalation anthrax, tularemia, and plague.
With a strong emphasis on project planning and assay development, Nick is adept at navigating the intricacies of start-up dynamics while fostering a culture of innovation and scientific rigor. His passion for leveraging cutting-edge methodologies and hardware diagnostics positions AQR at the forefront of the life sciences industry, driving meaningful advancements in therapeutics that can significantly impact public health.